The European market has shown resilience, with the pan-European STOXX Europe 600 Index rising by 1.77% due to relief from the reopening of the U.S. federal government, although enthusiasm for artificial intelligence investments has cooled. In this context, identifying promising investment opportunities requires a focus on stocks that combine potential growth with strong fundamentals. Penny stocks may be an outdated term, but they continue to represent intriguing possibilities in smaller or newer companies; when these are supported by sound financial health and clear growth prospects, they can offer significant value and potential upside in today's market landscape.
Top 10 Penny Stocks In Europe
| Name | Share Price | Market Cap | Rewards & Risks |
| Ariston Holding (BIT:ARIS) | €3.89 | €1.35B | ✅ 5 ⚠️ 2 View Analysis > |
| Orthex Oyj (HLSE:ORTHEX) | €4.70 | €83.47M | ✅ 4 ⚠️ 1 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (DB:0QM) | €0.37 | €241.45M | ✅ 3 ⚠️ 3 View Analysis > |
| Libertas 7 (BME:LIB) | €3.12 | €66.18M | ✅ 3 ⚠️ 3 View Analysis > |
| Hultstrom Group (OM:HULT B) | SEK3.46 | SEK210.5M | ✅ 2 ⚠️ 2 View Analysis > |
| ForFarmers (ENXTAM:FFARM) | €4.315 | €381.38M | ✅ 4 ⚠️ 1 View Analysis > |
| High (ENXTPA:HCO) | €3.99 | €78.05M | ✅ 1 ⚠️ 5 View Analysis > |
| Deceuninck (ENXTBR:DECB) | €2.135 | €295.1M | ✅ 3 ⚠️ 1 View Analysis > |
| Netgem (ENXTPA:ALNTG) | €0.86 | €28.8M | ✅ 2 ⚠️ 2 View Analysis > |
Click here to see the full list of 277 stocks from our European Penny Stocks screener.
Let's uncover some gems from our specialized screener.
Aelis Farma (ENXTPA:AELIS)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Aelis Farma SA is a clinical-stage biopharmaceutical company based in France that specializes in discovering and developing drug candidates for central nervous system disorders, with a market cap of €15.29 million.
Operations: The company generates €2.33 million in revenue from its research and development of pharmaceutical products.
Market Cap: €15.29M
Aelis Farma, a clinical-stage biopharmaceutical company, is navigating the challenges typical of penny stocks with its current pre-revenue status and unprofitability. Despite reporting a net loss of €4.32 million for the first half of 2025, the company maintains a strong balance sheet with short-term assets exceeding both short and long-term liabilities. The recent inclusion in the CAC Small and All-Tradable Indexes may enhance its visibility among investors. While Aelis has managed to reduce its debt-to-equity ratio significantly over five years, it faces high share price volatility and limited cash runway if free cash flow continues to decline at historical rates.
- Jump into the full analysis health report here for a deeper understanding of Aelis Farma.
- Review our growth performance report to gain insights into Aelis Farma's future.
Bambuser (OM:BUSER)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Bambuser AB (publ) operates a cloud-based video commerce platform with a market cap of SEK94.63 million.
Operations: The company generates revenue from its Internet Telephone segment, which amounts to SEK86.67 million.
Market Cap: SEK94.63M
Bambuser AB, operating in the video commerce sector, faces typical challenges of penny stocks, marked by ongoing unprofitability and high share price volatility. The company reported a net loss of SEK 22.03 million for Q3 2025, with declining sales compared to the previous year. Despite this, Bambuser's short-term assets significantly exceed its liabilities and it remains debt-free. Recent strategic partnerships like that with Power highlight potential growth avenues through live commerce initiatives. A follow-on equity offering of SEK 15.99 million could bolster financial stability as it navigates market dynamics and seeks revenue growth opportunities.
- Click to explore a detailed breakdown of our findings in Bambuser's financial health report.
- Evaluate Bambuser's historical performance by accessing our past performance report.
Hultstrom Group (OM:HULT B)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Hultstrom Group AB (publ) offers project management and consulting services across Sweden, Europe, Asia, and Africa, with a market cap of SEK210.50 million.
Operations: The company generates SEK312.29 million from its project management revenue segment.
Market Cap: SEK210.5M
Hultstrom Group AB (publ) presents a mixed picture typical of penny stocks, with strengths in financial stability and profitability. The company benefits from high-quality earnings and robust interest coverage, as its EBIT covers interest payments 16.1 times over. Its debt is well-managed, with operating cash flow covering it by a very large margin, and short-term assets exceeding liabilities comfortably. However, the board's lack of experience could be a concern for investors seeking seasoned leadership. Despite recent profit growth trailing its five-year average, Hultstrom outpaced industry performance last year with an 18.4% earnings increase.
- Click here and access our complete financial health analysis report to understand the dynamics of Hultstrom Group.
- Learn about Hultstrom Group's historical performance here.
Seize The Opportunity
- Click through to start exploring the rest of the 274 European Penny Stocks now.
- Want To Explore Some Alternatives? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Aelis Farma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com